Effects of nitric oxide on the biological behavior of HepG2 human hepatocellular carcinoma cells

Zhou,Lei; Zhang,Heng; Wu,Jie

doi:10.3892/etm.2016.3128

Effects of nitric oxide on the biological behavior of HepG2 human hepatocellular carcinoma cells

Authors:
- Lei Zhou
- Heng Zhang
- Jie Wu
View Affiliations

Affiliations: Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: March 2, 2016 https://doi.org/10.3892/etm.2016.3128
Pages: 1875-1880

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Many studies have found the function of nitric oxide (NO) in cancer as a pro‑neoplastic vs. an anti‑neoplastic effector, but the role of NO in hepatocellular carcinoma (HCC) remains unclear. The present study aimed to investigate the effects of nitric oxide (NO) on the biological behavior of the human hepatocellular carcinoma cell line HepG2. HepG2 cell was cultured in vitro and treated with or without sodium nitroprusside (SNP), a NO donor. Subsequently, we evaluated the effects of NO in cell proliferation, cell cycle, apoptosis, migration and invasion by MTT assay, flow cytometry, wound healing assay and Matrigel invasion assay. We demonstrate that NO significantly inhibited HepG2 cell proliferation by inducing G0/G1 phase arrest in a dose‑dependent manner. In addition, compared to the control group, cells treated with SNP showed obviously higher apoptosis ratios in a dose‑dependent manner. Furthermore, we revealed that NO effectively inhibited the ability of migration and invasion of HepG2 cells. Taken together, our results suggested that NO has an important role in the regulation of biological behavior in HepG2 cells and the potential for use in the prevention and treatment of HCC.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	International Agency for Research on Cancer: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. http://www-dep.iarc.fr/Accessed. August 10–2014
3	Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, et al: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 38:200–207. 2003. View Article : Google Scholar : PubMed/NCBI
4	Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Suzuki T, Shimamura T, Furukawa H, Matsushita M, Todo S, et al: Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol. 16:1560–1571. 2009. View Article : Google Scholar : PubMed/NCBI
5	Huerta S, Chilka S and Bonavida B: Nitric oxide donors: Novel cancer therapeutics (review). Int J Oncol. 33:909–927. 2008.PubMed/NCBI
6	Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer. 72:41–44. 1995. View Article : Google Scholar : PubMed/NCBI
7	Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Ose SM, Klein S, Shields PG, Billiar TR and Harris CC: Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58:334–341. 1998.PubMed/NCBI
8	Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC and Grimm EA: Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 6:4768–4775. 2000.PubMed/NCBI
9	Masri FA, Comhair SA, Koeck T, Xu W, Janocha A, Ghosh S, Dweik RA, Golish J, Kinter M, Stuehr DJ, et al: Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med. 172:597–605. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zhou L, Wang Y, Tian DA, Yang J and Yang YZ: Decreased levels of nitric oxide production and nitric oxide synthase-2 expression are associated with the development and metastasis of hepatocellular carcinoma. Mol Med Rep. 6:1261–1266. 2012.PubMed/NCBI
11	Hu J and Verkman AS: Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J. 20:1892–1894. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, Doja S, Jiang W, Subleski J, Shorts L, et al: Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res. 64:6849–6853. 2004. View Article : Google Scholar : PubMed/NCBI
13	Chao JI, Kuo PC and Hsu TS: Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 279:20267–20276. 2004. View Article : Google Scholar : PubMed/NCBI
14	Rishi L, Dhiman R, Raje M and Majumdar S: Nitric oxide induces apoptosis in cutaneous T cell lymphoma (HuT-78) by downregulating constitutive NF-kappaB. Biochim Biophys Acta. 1770:1230–1239. 2007. View Article : Google Scholar : PubMed/NCBI
15	Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D and Yeung K: Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo-and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide. 19:152–157. 2008. View Article : Google Scholar : PubMed/NCBI
16	Sang J, Chen Y and Tao Y: Nitric oxide inhibits gastric cancer cell growth through the modulation of the Akt pathway. Mol Med Rep. 4:1163–1167. 2011.PubMed/NCBI
17	Hickok JR, Sahni S, Mikhed Y, Bonini MG and Thomas DD: Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: Role of chelatable iron. J Biol Chem. 286:41413–41424. 2011. View Article : Google Scholar : PubMed/NCBI
18	Bonavida B and Baritaki S: Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-kB/Snail/YY1/RKIP circuitry. Nitric Oxide. 24:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
19	Elledge SJ: Cell cycle checkpoints: Preventing an identity crisis. Science. 274:1664–1672. 1996. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Ji P, Liu J, Broaddus RR, Xue F and Zhang W: Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer. 13:82009. View Article : Google Scholar
21	Jacobson MD, Weil M and Raff MC: Programmed cell death in animal development. Cell. 88:347–354. 1997. View Article : Google Scholar : PubMed/NCBI
22	Onishi Y, Ueha T, Kawamoto T, Hara H, Toda M, Harada R, Minoda M, Kurosaka M and Akisue T: Regulation of mitochondrial proliferation by PGC-1α induces cellular apoptosis in musculoskeletal malignancies. Sci Rep. 4:39162014. View Article : Google Scholar : PubMed/NCBI
23	Sun SY, Hail N Jr and Lotan R: Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst. 96:662–672. 2004. View Article : Google Scholar : PubMed/NCBI
24	Yin X, Zhang J, Li X, Liu D, Feng C, Liang R, Zhuang K, Cai C, Xue X, Jing F, et al: DADS suppresses human esophageal xenograft tumors through RAF/MEK/ERK and mitochondria-dependent pathways. Int J Mol Sci. 15:12422–12441. 2014. View Article : Google Scholar : PubMed/NCBI
25	Tang ZY: Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol. 7:445–454. 2001. View Article : Google Scholar : PubMed/NCBI
26	Wang F, Zhang R, Xia T, Hsu E, Cai Y, Gu Z and Hankinson O: Inhibitory effects of nitric oxide on invasion of human cancer cells. Cancer Lett. 257:274–282. 2007. View Article : Google Scholar : PubMed/NCBI
27	Sanuphan A, Chunhacha P, Pongrakhananon V and Chanvorachote P: Long-term nitric oxide exposure enhances lung cancer cell migration. Biomed Res Int. 2013:1869722013. View Article : Google Scholar : PubMed/NCBI